Evolution of metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at a hospital in Saudi Arabia (Q43562266)

24 November 2017

Evolution of metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at a hospital in Saudi Arabia (English)

1 reference

24 November 2017

0 references

1 reference

1 reference

1 reference

Al-Qurashi AR

1

1 reference

PubMed ID

11282271

24 November 2017

El-Morsy F

series ordinal

2

1 reference

PubMed ID

11282271

24 November 2017

Al-Quorain AA

series ordinal

3

1 reference

24 November 2017

1 March 2001

1 reference

International Journal of Antimicrobial Agents

24 November 2017

1 reference

24 November 2017

17

1 reference

24 November 2017

3

1 reference

24 November 2017

233-236

1 reference

Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

Duodenal ulcer relapse after eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

Treatment of peptic ulcers caused by Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

Treatment of Helicobacter pylori infection: a review of the world literature

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

Antibiotic resistance problems with Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

Anti-helicobacter regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900336-8

7 January 2021

10.1016/S0924-8579(00)00336-8

Identifiers

DOI

1 reference

24 November 2017

1 reference

PubMed ID

11282271